Ozempic and Mounjaro NAION Eye Warning (2026): What the Data Shows
[News · Drug safety]

Ozempic and Mounjaro NAION Eye Warning (2026): What the Data Shows

FDA Drug Safety Communication, November 9, 2026 · 126 trials · Sentinel study · Checked November 18, 2026

Published · By Ethen Amezquita

Short answer: On November 9, 2026, FDA said that drugs in the class of Ozempic, Wegovy, Mounjaro and Zepbound may raise the risk of NAION, a rare eye condition that causes sudden, painless vision loss in one eye, and told every maker to add it to the Warnings and Precautions section of the label. In FDA's pooled look at 126 randomized trials, NAION was rare in both groups: 6.4 cases per 100,000 person-years on these drugs vs 3.8 on comparators (10 cases vs 5). FDA's advice is to get help right away for sudden vision changes in one eye, and to talk with a clinician about stopping the drug if NAION is diagnosed.

This is the first time FDA has asked for a NAION warning on these labels. Below is what FDA announced, the data it used, how big the risk looks, and what FDA tells patients to do. We read FDA's communication, the study it cites, and the current labels on DailyMed on November 18, 2026.

What FDA announced on November 9

FDA issued a Drug Safety Communication and a MedWatch alert on November 9, 2026. It concluded there is a "potential increased risk of rare NAION events" with this drug class and is requiring the makers of all of them to add NAION to the Warnings and Precautions section of their labels. FDA says NAION cases have been reported with every one of these drugs on the market.

The drugs FDA lists are Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Victoza, Saxenda and Xultophy (liraglutide), Trulicity (dulaglutide), Soliqua (lixisenatide), Foundayo (orforglipron) and generic exenatide (Byetta itself was withdrawn for reasons FDA says were not safety or effectiveness).

When we checked on November 18, 2026, the labels posted on DailyMed did not mention NAION yet: Ozempic injection (June 10, 2026), Wegovy (June 30, 2026), and Mounjaro and Zepbound (September 2, 2026). The new wording should appear as each maker updates its label. FDA's communication does not mention compounded semaglutide or tirzepatide.

What NAION is

NAION stands for non-arteritic anterior ischemic optic neuropathy: reduced blood flow damages the optic nerve, the cable from the eye to the brain. FDA describes it as sudden, painless vision loss in one eye, often noticed on waking, with blurry or missing areas of vision, colors that look off, or less sharp central vision. The loss can be permanent. After NAION in one eye, the other eye is at higher risk. See our NAION glossary entry.

NAION happens without these drugs too. FDA cites a background rate of 2.3 to 10.2 cases per 100,000 people per year in adults over 50. Risk factors FDA lists include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease, several of which are common in people who take these drugs.

The data FDA used

EvidenceWhat it found
Pooled analysis of 126 randomized trials (134,253 patients; 288,879 person-years)15 probable NAION cases: 10 on the drugs, 5 on placebo, none on other diabetes drugs. Rate 6.4 vs 3.8 per 100,000 person-years.
FDA Sentinel study: adults with type 2 diabetes who started one of these drugs, an SGLT-2 inhibitor or a DPP-4 inhibitor, 2019 to 2024Rates of 26 to 32 per 100,000 person-years across groups (30 to 32 on these drugs). Versus SGLT-2 inhibitors: hazard ratio 1.19 (95% CI 0.91 to 1.54), not statistically significant. Versus DPP-4 inhibitors: hazard ratio 1.43 (1.02 to 2.01), a higher risk.
Published observational studiesFDA says the most rigorous ones consistently found more NAION in people with type 2 diabetes starting these drugs than in those starting DPP-4 or SGLT-2 inhibitors.
Adverse event reportsHard to interpret, FDA says, because NAION risk factors overlap with the conditions these drugs treat.
Animal studiesNo mechanism found.

All figures in the table are from FDA's November 9 communication.

How big is the risk?

Small in absolute terms. In the trial data, 6.4 vs 3.8 cases per 100,000 person-years is a difference of about 2.6 cases per 100,000 person-years (our arithmetic from FDA's numbers). Put another way, if 100,000 people took one of these drugs for a year, the trials suggest a few more NAION cases than without it. The trial count is also tiny: 15 cases in total.

The 2024 study that started the concern found much larger numbers. In Hathaway et al., JAMA Ophthalmology 2024, patients prescribed semaglutide had a higher NAION risk than those on other drugs: hazard ratio 4.28 (95% CI 1.62 to 11.29) in type 2 diabetes and 7.64 (2.21 to 26.36) in overweight or obesity. That study used records from patients already seen by neuro-ophthalmologists at one hospital, and its authors said future study is needed to assess causality. FDA noted "several limitations" in it but decided more review was warranted.

Europe reached a similar conclusion first. In June 2025, the European Medicines Agency's safety committee concluded NAION is a "very rare" side effect of semaglutide, meaning up to 1 in 10,000 people. Our vision problems answer page covers that ruling and the separate diabetic retinopathy warning.

What FDA tells patients and clinicians

  • Know the symptoms: sudden, painless vision loss or blurring in one eye, missing areas of vision, or color changes. Contact a health care professional right away if they happen.
  • If you have had NAION, talk with your clinician about whether to keep taking the drug or stop it.
  • For clinicians, FDA says to refer suspected NAION promptly to an eye doctor and to "consider discontinuing" the drug in patients who develop NAION unless the benefits clearly outweigh the risk.
  • Report side effects to FDA through MedWatch or by calling 1-800-332-1088 for a form.

The communication does not tell people without symptoms to stop their medicine.

What this means for you

For most people on Ozempic, Mounjaro or a similar drug, this is a rare risk to know about, not a reason to panic. The one thing to act on is speed: sudden vision loss in one eye is a same-day call. If you track your doses, note the date any vision change started and your dose at the time, so your eye doctor has the timeline. Our guide to tracking doses and side effects shows what to log. For the other big label warning on these drugs, see the thyroid cancer boxed warning.


Frequently asked questions

What did FDA announce about NAION on November 9, 2026?+
FDA said semaglutide, tirzepatide and similar drugs may raise the risk of NAION, a rare cause of sudden vision loss in one eye, and is requiring every maker to add it to the Warnings and Precautions section of the label.
How common is NAION on Ozempic or Mounjaro?+
Rare. In FDA's pooled analysis of 126 randomized trials there were 15 probable cases in total: 6.4 per 100,000 person-years on these drugs vs 3.8 on comparators.
Should I stop Ozempic or Mounjaro because of the NAION warning?+
FDA does not tell people without symptoms to stop. It says to get help right away for sudden vision changes in one eye, and to discuss stopping with a clinician if NAION is diagnosed.
What are the symptoms of NAION?+
Sudden, painless vision loss in one eye, often noticed on waking, with blurry or missing areas of vision, colors that look off, or less sharp central vision.
Does the NAION warning apply to Wegovy and Zepbound too?+
Yes. FDA's list covers all approved drugs in the class, including Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity and Foundayo.

Sources

Every fact in this article comes from one of these sources, checked on November 18, 2026. This article is for education. It is not medical advice, and nothing here is a dose recommendation.

  1. U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication, November 9, 2026. fda.gov
  2. U.S. Food and Drug Administration. MedWatch alert on the same labeling change, November 9, 2026. fda.gov
  3. Hathaway JT, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. PMID 38958939. PubMed
  4. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025. ema.europa.eu
  5. Ozempic (semaglutide) injection label, Novo Nordisk, DailyMed version of June 10, 2026. DailyMed
  6. Wegovy (semaglutide) label, Novo Nordisk, DailyMed version of June 30, 2026. DailyMed
  7. Mounjaro (tirzepatide) label, Eli Lilly, DailyMed version of September 2, 2026. DailyMed
  8. Zepbound (tirzepatide) label, Eli Lilly, DailyMed version of September 2, 2026. DailyMed
  9. U.S. Food and Drug Administration. MedWatch online reporting. accessdata.fda.gov